Table 2. Risk of bias according to The Cochrane Collaboration's 'Risk of bias' tool.
Publi-cation | Ran-dom sequ-ence genera-tion | Allo-cation conceal-ment | Blin-ding of partici-pants and personnel | Blin-ding of out-come assess-ment | Incom-plete out-come data | Selec-tive repor-ting | Other sources for bias | Sum-mary |
---|---|---|---|---|---|---|---|---|
Ser-retta et al. [2] | Unclear | Yes | Unclear | Unclear | Yes | Unclear | Co-authors employed by Astra-Zeneca | Unclear risk of bias |
Bedog-netti et al. [9] | Yes | Yes | No | No | Yes | Unclear | High risk of bias | |
Fradet et al. [10] | Yes | Yes | Yes | Yes | Yes | Unclear | Funding by Astra-Zeneca | Low risk of bias |
Saltz-stein et al. [4] | Yes | Yes | Yes | Yes | Yes | Unclear | Co-authors employed by Astra-Zeneca | Low risk of bias |
Boc-cardo et al. [7] | Yes | Unclear | Yes | Yes | Yes | Unclear | Funding by Astra-Zeneca | Unclear risk of bias |
Ozen et al. [11] | Unclear | Yes | No | No | Yes | Unclear | High risk of bias | |
Van Poppel et al. [12] | No | No | No | No | Yes | Unclear | Sponsored by Astra-Zeneca | High risk of bias |
Tyrrell et al. [13] | Yes | Yes | Yes | Yes | Yes | Unclear | Funding by Astra-Zeneca. Co-authors employed by Astra-Zeneca | Low risk of bias |
Wid-mark et al. [14] | Unclear | Unclear | No | No | Yes | Unclear | High risk of bias | |
Per-doná et al. [15] Di Loren-zo et al. [16] | Yes | Yes | No | No | Yes | Unclear | High risk of bias |